Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06522334

Enrollment

400

Registered

2024-07-26

Start date

2024-02-28

Completion date

2034-02-28

Last updated

2025-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease

Brief summary

The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death. There are no additional interventions regarding this registry.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diagnosis of interstitial lung disease * written informed consent

Exclusion criteria

* to not comprehend and rightfully judge participation

Design outcomes

Primary

Measure	Time frame	Description
Mortality	10 years	Mortality caused by interstitial lung disease
Loss of lung function	2 years	FVC and DLCO loss within 24 months

Secondary

Measure	Time frame	Description
Prevalence	10 years	Prevalence of the different interstitial lung diseases in Austria
Response to drugs	10 years	Response to immunosuppressive/immunomodulating/antifibrotic drugs

Countries

Austria

Outcome results